EYLEA

Opthea IPO: What Investors Should Know About The Genentech, Regeneron Challenger

IPO Outlook: Solar Power Company Array Technologies, Chinese Retailer Miniso Lead Possible 9 IPO Week

Regeneron Snags Upgrade On Reduced Prospects For Rival Eye Disorder Drug

IPO Outlook: Solar Power Company Array Technologies, Chinese Retailer Miniso Lead Possible 9 IPO Week

Regeneron Snags Upgrade On Reduced Prospects For Rival Eye Disorder Drug

Regeneron's Eylea Prefilled Syringe Clears FDA Hurdle

Clearside Biomedical Plunges 60% Following Phase 3 Study Results

Regeneron's Eylea Prefilled Syringe Clears FDA Hurdle

Clearside Biomedical Plunges 60% Following Phase 3 Study Results

Attention Biotech Investors: Mark Your Calendar For These August PDUFA Dates

Canaccord Slices Regeneron Price Target 32% On Eylea, Dupixent Challenges

EYLEA Recent News

The Prospects For CHS-3351, Coherus' Most Underappreciated Asset

Alimera's Commercial Steroid Implant For Diabetic Macular Edema, Explored

Do Analysts See A Path Forward For Ophthotech's Fovista?

Stay Of Court Injunction A Mild Positive For Regeneron

Regeneron Eyes A Comeback In 2017

One Way To Look At The Ophthotech-Regeneron Pair Trade

Imprimis Pharmaceutical After Its Phenomenal Quarter: 'Shocking' Statistics, Simplification And A Trifecta For Success

Regeneron Is 'One Of The Stronger Growers In Biotech'

Regeneron Gains 4% Following Q1 Earnings Release

Regeneron Pharmaceuticals Loses 7% Following Q4 Miss

Chardan Downgrades Regeneron Pharmaceuticals, Notes Valuation Concerns

Why Avalanche Biotechnologies Is Coming Off A Big Day

Regeneron Earnings: Small Growth Expected, Driven By Eylea

UPDATE: Barclays Initiates Coverage On Regeneron

Markets Marginally Higher On Light Volume And Encouraging Geopolitical Developments

Top Trending Tickers On StockTwits For February 11